2008American family physicianRequires access

Becaplermin (Regranex) for Diabetic Foot Ulcers

Courtney I. Jarvis

Open publisher page 6 citations

Abstract

Although patients treated with becaplermin are more likely to experience complete and faster ulcer healing than patients continuing good wound care alone, the increased risk of cancer mortality and significant cost outweigh the possible benefits in most patients.

About this research paper

What this paper is about

Although patients treated with becaplermin are more likely to experience complete and faster ulcer healing than patients continuing good wound care alone, the increased risk of cancer mortality and significant cost outweigh the possible benefits in most patients.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Although patients treated with becaplermin are more likely to experience complete and faster ulcer healing than patients continuing good wound care alone, the increased risk of cancer mortality and significant cost outweigh the possible benefits in most patients.

Key concepts: Medicine, Diabetic foot, Diabetic foot ulcer, Wound care, Intensive care medicine, Diabetic ulcers, Foot (prosody), Surgery

Related papers

Back to paper searchBrowse research topicsOriginal source
Becaplermin (Regranex) for Diabetic Foot Ulcers — Research Paper | ScholarLens